Friday, July 20, 2018 News Recap: Zepatier Plus Sovaldi Beats Hep C in Those with Cirrhosis and Genotype 3. Merck’s Zepatier (grazoprevir/elbasvir) plus Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, cured HCV genotype 3 at high rates in a recent trial. The results were published in Hepatology. Dirty Ottawa clinic equipment may have affected 4,600 patients. Thousands of people who underwent minor surgery at a west Ottawa medical...
Merck’s Zepatier (grazoprevir/elbasvir) plus Gilead Sciences’ Sovaldi (sofosbuvir), with or without ribavirin, cured genotype 3 of hepatitis C virus (HCV) at high rates in a recent trial. Publishing their findings in the journal Hepatology, researchers conducted a Phase II randomized open-label study, known as C-ISLE, of Zepatier plus Sovaldi with or without ribavirin among those with genotype 3 of HCV and compensated cirrhosis (the milder form of the sev
Friday, April 28, 2017 News Recap Canada New Canadian Testing Guidelines Released: On April 24, 2017, The Canadian Task Force on Preventative Health Care (CTFPHC) published its HCV Screening Guidelines in the CMAJ. The guidelines make the recommendation to continue screening those with known risk factors, but does not include a recommendation to screen the age cohort born between 1945-1975, which has been recommended by many of Canada’s top liver sp...
AbbVie is aiming to steal sales from hep C drugs from Gilead and BMS with a new combination offering a shorter, eight-week treatment for the most difficult-to-treat form of the disease. Results presented at the International Liver Congress (ILC) in Amsterdam showed 95% of genotype 3 patients on its pan-genotypic regimen of glecaprevir+pibrentasvir were free of disease, 12 weeks after completing an eight-week treatment course. The results were based on
Within the next few years, several pipeline hepatitis C (HCV) drugs are expected to be approved in the United States, ensuring that even the most difficult-to-treat patients will soon be able to be cured, according to experts interviewed at The Liver Meeting in Boston. "Very few patients are being warehoused because there are only a few very niche special populations left," noted Robert Brown, M.D., M.P.H., Gladys and Roland Harriman Professor of Medicine
Natco Pharma has signed a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Daclatasvir, used for the treatment of chronic hepatitis C.Natco Pharma, in a BSE filing today said: “It has signed a non-exclusive, royalty free licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol—Myers Squibb’s
"ABT-493 is more potent against genotype 3 than other HCV protease inhibitors, including products being developed by Merck (grazoprevir) and Gilead (GS-9451), and ABT-530 has demonstrated higher potency than most other NS5A inhibitors across all genotypes."A combination of two experimental direct-acting antivirals developed by AbbVie cured 93%-97% of people with genotype 3 hepatitis C infection after a 12-week course of treatment, Paul Kwo of Indiana Unive...
An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis C virus (HCV), including treatment-experienced people with HCV genotype 3 and liver cirrhosis, according to results presented on Sunday at the 2015 AASLD Liver Meeting in San Francisco, USA. A 6-week regimen appeared inadequate, however, and more than 8 weeks may be needed
A combination of two experimental direct-acting antivirals developed by AbbVie cured 97%-100% of non-cirrhotic people with genotype 1 hepatitis C infection in a mid-stage phase 2 study presented this week at the AASLD Liver Meeting in San Francisco.The SURVEYOR-1 study assessed the effectiveness and safety of two experimental next-generation direct-acting antivirals. ABT-493 is an HCV NS3/4A protease inhibitor active against all genotypes of hepatitis C. A
Hepatitis C’s genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works. Vincent LeRoy, MD, of the Centre Hospitalier Universitaire de Grenoble, La Tronche France, and colleagues at other institutions reported on a trial known as ALLY-3+. Fifty patients with HCV-GT-3 were treated and most had already had other treatments. The patients got daclatasvir (Dak